Skip to content

A.R.PHARMA

Active Private limited companyfounded 2011active for 15 yearsChaussée de Charleroi 16, 6061 CharleroiKBO/BCE: BE 0837.766.531

Lifetime

15 annual accounts with figures on one time axis
peak of €460,197 in 2022
€399,339▼ 2.1%
peak of €219,174 in 2022
€157,946▼ 4.3%
peak of €1.5m in 2025
€1.5m▲ 12.0%
€608,613▼ 9.0%
peak of 1.8 FTE in 2024
1.6 FTE▼ 11.1%
Board1 name since 2011
1 director
Documentsfilings and deeds
25-08-202625 days late
2025abbreviated format
Staff from 1.8 FTE to 1.6 FTE

Key points

from the 2025 annual accounts

Equity

€1.5m ▲ 12.0%

A.R.PHARMA has made a profit in every financial year since 2011.

Filings

15 annual accounts since 2011
AprilJune31 JulyOctober201520202025

Ten of the last ten came late. The 2019 accounts came in latest, 91 days after the end of the period.

Position in the sector

€1.5m

More equity than 90% of companies in retail trade. The sector median is €314,586, over 13,306 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 34,728 companies had the same profile as A.R.PHARMA has now. Each dot stands for 87 companies, two years later.

95.2%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,728 companies, not a prediction for A.R.PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 12-07-2011
  • 186 sharesdeed of 25-07-2011
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0837766531
Merger: A.R. PHARMA takes over HUMBLET PHARMA changes role from manager to director · A.R. PHARMA resigns as mandate holder · The company holds all the shares of HUMBLET PHARMA · General meeting of 30-12-2020 · Gazette deed
Merger proposal: A.R.PHARMA takes over HUMBLET PHARMA Gazette deed
Merger proposal: A.R. PHARMA takes over HUMBLET PHARMA Gazette deed
All 28 events

Comparable companies

same main activity, similar in size and age
Company
A.R.PHARMA Charleroi €2.1m €399,339 70.8% 1.6
Pharmacie Gosselin-Obourg Mons €1.8m €388,077 71.7% 2.1
APOTHEEK GAVERLAND Beveren-Kruibeke-Zwijndrecht €2.1m €388,106 29.5% 1.4
APOTHEEK GEEROMS Ninove €1.7m €406,355 46.3% 1.8
Apotheek Cindy Nachtergaele Kruisem €2.2m €447,512 47.3% 1.7
APOTHEEK DE LOORE ZWEVEZELE Wingene €2.1m €309,109 15.5% 1.7
APOTHEEK COENEN BART Alken €1.8m €373,077 30.7% 2

These companies have the same main activity as A.R.PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.7m and €2.2m, founded between 2008 and 2014.

Official details

Source: KBO
Status
Active since 12-07-2011Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.200.804.7896061 Charleroi, since 26-07-2011
Financial year end
31 December
Peppol
Reachable since 19-11-2025
Company details

Annual accounts 2025

≈ €1.4mestimated
€2.1m▲ 4.9%
Employeeson 31-12-2025
2=
Filing
Filed on 25-08-2026
Financials

Insights on A.R.PHARMA

A.R.PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €63,012 in 2011 to €399,339 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about A.R.PHARMA

What is the company number of A.R.PHARMA?
The company number of A.R.PHARMA is 0837.766.531. The VAT number is the same number with BE in front: BE 0837.766.531.
Where is A.R.PHARMA based?
The registered office is at Chaussée de Charleroi 16, 6061 Charleroi.Company details
What does A.R.PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of A.R.PHARMA?
A.R.PHARMA is a private limited company (BV).
When was A.R.PHARMA founded?
A.R.PHARMA was founded on 12-07-2011.
Is A.R.PHARMA still active?
Yes, A.R.PHARMA is an active enterprise in the KBO register.
How many employees does A.R.PHARMA have?
A.R.PHARMA had an average of 1.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of A.R.PHARMA?
The turnover in financial year 2025 is about €1.4m. This figure is estimated from the gross margin of €399,339 and 42 comparable companies (NACE 477). It probably lies between €1.1m and €1.9m.
Is A.R.PHARMA profitable?
In financial year 2025, A.R.PHARMA made a profit of €157,946.
Where can I find the annual accounts of A.R.PHARMA?
A.R.PHARMA filed 15 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of A.R.PHARMA due?
A.R.PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.